Decreased levels of pro-inflammatory cytokines IL-1β, IL-6, and VEGF were observed after treatment with BromAc®, indicating possible modulation of the inflammasome-associated pathway, which plays a role during COVID-19 (11, 44). This evidence concerns the gene IL6 and COVID-19.